Top-News
Pharmazeutika Belgien

Galapagos NV News

Aktie
WKN:  A0EAT9 ISIN:  BE0003818359 US-Symbol:  GLPGF
25,48 €
+0,58 €
+2,33%
31.05.24 14:26:22
Handeln Depot/Watchlist
Aktienanzahl *
65,90 Mio.
Marktkapitalisierung *
1,69 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 02.05.2024

Unternehmensmeldungen

15.05.24 - GlobeNewswire
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration ...
09.03.17 - DGAP
Pharnext gibt Forschungs- und Entwicklungsvereinbarung mit Galapagos zum Aufbau einer neuen Pipeline synergistischer Wirkstoffkombinationen bekannt
DGAP-News: Pharnext S.A. / Schlagwort(e): Kooperation Pharnext gibt Forschungs- und Entwicklungsvereinbarung mit Galapagos zum Aufbau einer neuen Pipeline synergistischer ...
10.11.11 - Hugin
Galapagos business update
Mechelen, Belgium; 10 November 2011 - Galapagos NV (Euronext: GLPG) announces today that third quarter 2011 operational and financial results were in line with management ...
07.11.11 - Hugin
Galapagos to present results for selective JAK1 inhibitor in rheumatoid arthritis patients on 22 November 2011
GLPG0634 preclinical/Phase I poster presentation tomorrow at ACR 2011 Mechelen, Belgium; 7 November 2011- Galapagos NV (Euronext: GLPG) announced today that it will ...
04.11.11 - Hugin
Galapagos wins 2011 Scrip Award for Biotech Company of the Year
Mechelen, Belgium and London, UK; 4 November 2011 - Galapagos NV (Euronext: GLPG) announced that it won the prestigious Scrip Award for Biotech Company of the Year at last ...
12.10.11 - Hugin
Galapagos announces second extension to services collaboration with Chiesi
Mechelen, Belgium and Saffron Walden, UK; 12 October 2011 - Galapagos NV (Euronext: GLPG) announced today that its BioFocus service division has extended its collaboration ...
03.10.11 - Hugin
Servier and Galapagos initiate strategic alliance for innovative treatments in oncology
*  Joint discovery and development of novel small molecule therapies for cancer * Novel cancer targets coming from Servier and Galapagos * Research access payment of ¤2 ...
18.08.11 - Hugin
Galapagos and Genentech extend drug discovery collaboration
Mechelen, Belgium; 18 August 2011 - Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery ...
05.08.11 - Hugin
Galapagos announces half year results 2011
On track for building sizeable pipeline while maintaining strong cash position ·         Initiated four clinical trials to deliver efficacy or Proof-of- Mechanism data by year end ·         Full ...
20.07.11 - Hugin
Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492
* Follows successful outcome of first-​in-human clinical trial * Proof-​of-Mechanism study measures GLPG0492's effect on muscle function in healthy volunteers Mechelen, Belgium; ...
01.07.11 - Hugin
Galapagos increases share capital through warrant exercises
Mechelen, Belgium; 1 July 2011 - Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises. Since its inception in 1999, ...
28.06.11 - Hugin
Argenta signs integrated services agreement with Pulmagen Therapeutics
Mechelen, Belgium; 28 June 2011 - Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen ...
09.06.11 - Hugin
Galapagos initiates Phase II trial for GLPG0634
* Follows successful outcome of Phase I trials * Proof-​of-Concept study designed to assess efficacy in rheumatoid arthritis patients by year end * Selective JAK1 profile could ...
01.06.11 - Hugin
Evotec acquires compound management business from Galapagos
·         Evotec to further strengthen its integrated innovation offering with world-​class compound management ·         Synergies with Evotec's drug discovery alliance business ...
30.05.11 - Hugin
Ronald Brus resigns from the Galapagos Board
Mechelen, Belgium; 30 May 2011 - Galapagos NV (Euronext: GLPG) announced today that Dr Ronald Brus has resigned from the Board of Directors. Ronald Brus is President and ...
11.01.11 - Hugin
Galapagos receives ¤7.4 M milestone in arthritis alliance with GlaxoSmithKline
·         Completed first-​in-human trials for GLPG0555 ·         Alliance's second novel candidate drug, GLPG0778, enters clinic Mechelen, Belgium; 11 January 2011 - Galapagos NV ...
17.12.10 - Hugin
Galapagos' affiliate BioFocus extends collaboration with Amgen into 2012
Mechelen, Belgium; 17 December 2010 - Galapagos NV (Euronext: GLPG) announced today that its BioFocus service division has extended its contract with Amgen for 2011 and ...
16.12.10 - Hugin
Galapagos achieves milestones, broadens scope of Roche alliance
Mechelen, Belgium; 16 December 2010 - Galapagos NV (Euronext: GLPG) announced today that it has achieved ¤3.5 M in milestone payments in its strategic alliance with Roche ...
07.12.10 - Hugin
Galapagos increases share capital through warrant exercises
Mechelen, Belgium; 7 December 2010 - Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises. Since its inception in 1999, ...
02.12.10 - Hugin
Galapagos candidate cachexia drug, GLPG0492, shows good safety and profile suitable for once-daily oral dosing
·           Successful completion of first-​in-human trial for GLPG0492 ·           Plans to initiate extended dose and Proof of Concept studies in 2011 Mechelen, Belgium; 2 December ...

Newssuche

Videos

29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »